

\* \* \* \* \*  
FILE 'USPAT' ENTERED AT 08:01:18 ON 02 AUG 1999

\* \* \* \* \*  
\* U. S. P A T E N T T E X T F I L E \*  
\* \*  
\* THE WEEKLY PATENT TEXT AND IMAGE DATA IS CURRENT \*  
\* THROUGH July 27,1999 \*  
\* \*  
\* \*  
\* \* \* \* \*

=> s (conjugate# or complex)(p)(polypeptide# or oligopeptide# or peptide# or protein#)(p)(prostate(w)specific(w)antigen# or psa)

51260 CONJUGATE#  
337102 COMPLEX  
22308 POLYPEPTIDE#  
2306 OLIGOPEPTIDE#  
35368 PEPTIDE#  
86807 PROTEIN#  
4427 PROSTATE  
947936 SPECIFIC  
27063 ANTIGEN#  
2887 PSA

L1 32 (CONJUGATE# OR COMPLEX) (P) (POLYPEPTIDE# OR OLIGOPEPTIDE# OR  
PE PTIDE# OR PROTEIN#) (P) (PROSTATE(W)SPECIFIC(W)ANTIGEN# OR PS  
A)

=> d 11 1-32

1. 5,912,158, Jun. 15, 1999, Prostate specific antigen (PSA)-proteinase inhibitor complexes; Hans Lilja, et al., 435/226, 219; 530/350 [IMAGE AVAILABLE]

2. 5,912,135, Jun. 15, 1999, Methods for diagnosing benign prostatic diseases; Albert A. Luderer, et al., 435/7.4, 7.94; 436/64, 86 [IMAGE AVAILABLE]

3. 5,866,679, Feb. 2, 1999, Peptides; Deborah DeFeo-Jones, et al., 530/322, 324, 326, 328, 329 [IMAGE AVAILABLE]

4. 5,859,215, Jan. 12, 1999, Biospecific binding reactants labelled with luminescent lanthanide chelates and their use; Juan Carlos Rodriguez-Ubis, et al., 534/16; 424/9.34, 9.36, 9.6; 436/172; 546/2, 5, 6, 256 [IMAGE AVAILABLE]

5. 5,858,685, Jan. 12, 1999, Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis; Thomas A. Stamey, et al., 435/7.4, 7.21, 7.23, 212; 436/543; 530/350, 388.26, 388.85 [IMAGE AVAILABLE]

6. 5,849,904, Dec. 15, 1998, Isolated nucleic acid molecules which hybridize to polysialyl transferases; Rita Gerardy-Schahn, et al., 536/24.31; 435/6; 536/23.1, 24.32 [IMAGE AVAILABLE]

7. 5,830,680, Nov. 3, 1998, Unitary sandwich enzyme immunoassay cassette device and method of use; Mark E. Meyerhoff, et al., 435/7.92;

422/82.01, 82.02; 435/5, 6, 7.1, 7.9, 7.94, 975; 436/518, 525, 528, 807  
[IMAGE AVAILABLE]

8. 5,807,978, Sep. 15, 1998, Immunogenic peptides of prostate specific antigen; William J. Kokolus, et al., 530/300; 424/184.1, 185.1, 277.1; 530/326, 327, 403 [IMAGE AVAILABLE]

9. 5,780,247, Jul. 14, 1998, Process for separating and measuring trace components; Shinji Satomura, et al., 435/7.23; 422/68.1, 70; 435/7.1, 7.4, 7.9, 971, 973; 436/161, 514, 536, 538, 541, 824, 827; 530/412, 413, 416, 417 [IMAGE AVAILABLE]

10. 5,773,292, Jun. 30, 1998, Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood; Neil H. Bander, 435/332; 424/138.1, 141.1, 152.1, 155.1; 435/7.21, 7.23; 530/387.5, 387.7, 388.2, 388.8, 389.1, 389.7, 391.1, 391.3, 391.7 [IMAGE AVAILABLE]

11. 5,747,326, May 5, 1998, Isolated nucleic acid molecules which encode mammalian .alpha.2,8 polysialyl transferases; Rita Gerardy-Schahn, et al., 435/325, 69.1, 193, 252.3, 252.33, 320.1, 348, 358, 365; 530/350; 536/23.2, 23.5 [IMAGE AVAILABLE]

12. 5,736,142, Apr. 7, 1998, Alteration of immune response using pan DR-binding peptides; Alessandro Sette, et al., 424/185.1, 184.1, 193.1; 514/2, 15; 530/300, 327, 332, 868 [IMAGE AVAILABLE]

13. 5,733,868, Mar. 31, 1998, Poly(amino acid) adhesive tissue grafts; Dale R. Peterson, et al., 514/2; 156/328, 336; 524/20 [IMAGE AVAILABLE]

14. 5,723,302, Mar. 3, 1998, Detection of prostate-specific antigen in breast tumors; Eleftherios Diamandis, 435/7.1, 7.23, 7.72; 436/63, 64 [IMAGE AVAILABLE]

15. 5,710,007, Jan. 20, 1998, Methods for diagnosing prostatic adenocarcinoma; Albert A. Luderer, et al., 435/7.1, 7.23, 7.9, 7.92; 436/63, 64, 518 [IMAGE AVAILABLE]

16. 5,698,402, Dec. 16, 1997, Methods for diagnosing benign prostatic hyperplasia; Albert A. Luderer, et al., 435/7.4; 128/898; 435/7.94; 436/64, 86 [IMAGE AVAILABLE]

17. 5,677,194, Oct. 14, 1997, Process for rapid measurement of trace components; Shinji Satomura, et al., 436/501; 435/7.92, 7.93, 7.94; 436/530, 536, 538, 539, 540, 541, 805, 824, 827 [IMAGE AVAILABLE]

18. 5,672,480, Sep. 30, 1997, Immunoassays for prostate specific antigen; Barry L. Dowell, et al., 435/7.4, 7.94, 967, 975; 436/507; 530/391.1 [IMAGE AVAILABLE]

19. 5,658,725, Aug. 19, 1997, Acylated protein aggregates and their use in suppressing interference in immunoassays; Dittmar Schlieper, et al., 435/5; 422/55, 57, 61; 435/7.1, 7.5, 7.72, 7.92, 7.93, 7.94, 7.95, 805, 970, 975; 436/169, 170, 518; 530/345, 362, 363, 364 [IMAGE AVAILABLE]

20. 5,654,161, Aug. 5, 1997, Method for diagnosing prostate cancer; Prakash C. Tewari, 435/7.23, 7.9, 7.92; 436/64, 813 [IMAGE AVAILABLE]

21. 5,639,656, Jun. 17, 1997, Antibodies reactive with biological markers of benign prostate hyperplasia; George L. Wright, Jr., 435/344.1, 332; 530/388.2, 388.85, 389.1, 391.1, 391.3, 391.7 [IMAGE AVAILABLE]

22. 5,639,616, Jun. 17, 1997, Isolated nucleic acid encoding a ubiquitous nuclear receptor; Shutsung Liao, et al., 435/7.1, 69.1, 252.3, 320.1; 536/23.5, 24.3 [IMAGE AVAILABLE]

23. 5,599,686, Feb. 4, 1997, Peptides; Deborah DeFeo-Jones, et al., 435/23; 424/185.1; 435/4, 7.1, 7.23, 18, 24; 530/300, 322 [IMAGE AVAILABLE]
24. 5,599,677, Feb. 4, 1997, Immunoassays for prostate specific antigen; Barry L. Dowell, et al., 435/7.4, 7.23, 7.94, 962; 436/518, 548, 813 [IMAGE AVAILABLE]
25. 5,571,729, Nov. 5, 1996, Process for separating complex; Kenji Nakamura, et al., 436/541; 210/656, 660, 668; 435/7.1, 7.4; 436/538, 824; 530/412, 416, 417 [IMAGE AVAILABLE]
26. 5,545,530, Aug. 13, 1996, Process for measuring analyte in sample; Shinji Satomura, et al., 435/6, 7.1, 7.9, 7.93, 803, 971; 436/501, 507, 536, 538, 541, 812, 824 [IMAGE AVAILABLE]
27. 5,518,897, May 21, 1996, Recombinant biopesticide and method of use thereof; S. Edward Stevens, Jr., et al., 435/69.1; 424/93.1, 93.2, 93.4, 93.461; 435/252.3, 252.5, 320.1, 832; 536/22.1, 23.1, 23.4, 23.7, 23.71 [IMAGE AVAILABLE]
28. 5,516,639, May 14, 1996, Antibodies specific for human prostate glandular kallikrein; Donald J. Tindall, et al., 435/7.4, 7.92, 7.93, 7.94; 436/64, 547, 548, 813; 530/326, 387.1, 388.1, 388.26 [IMAGE AVAILABLE]
29. 5,487,990, Jan. 30, 1996, Glucose-regulated promoter of yeast acetyl-CoA hydrolase; John A. Smith, et al., 435/69.1, 254.2, 254.21, 254.22, 254.23, 320.1; 530/371; 536/24.1 [IMAGE AVAILABLE]
30. 5,447,838, Sep. 5, 1995, Protein-dye conjugate for confirmation of correct dilution of calibrators; Bruce Meiklejohn, et al., 435/5, 6, 7.1, 7.2, 7.21, 7.23, 7.4, 7.92, 7.93, 7.94, 7.95, 967; 436/8, 10, 56, 501 [IMAGE AVAILABLE]
31. 5,354,654, Oct. 11, 1994, Lyophilized ligand-receptor complexes for assays and sensors; Frances S. Ligler, et al., 435/5, 6, 7.1, 7.21, 7.22, 7.23, 7.24, 7.25, 7.3, 7.31, 7.32, 7.33, 7.34, 7.35, 7.36, 7.4, 7.8, 963; 436/500, 501, 506, 513, 518 [IMAGE AVAILABLE]
32. 4,336,185, Jun. 22, 1982, Folic acid derivatives; Gordon D. Niswender, 530/363; 436/505; 530/380, 381, 386, 389.8, 405, 409, 806; 544/261 [IMAGE AVAILABLE]

=> d l1 kwic 1

US PAT NO: 5,912,158 [IMAGE AVAILABLE]

L1: 1 of 32

ABSTRACT:

**Prostate specific antigen (PSA)** is a **protein** that can form complexes with proteinase inhibitors such as .alpha..sub.1 -antichymotrypsin. The invention is characterized in that the measurement of the ratio of free **PSA** to **PSA** bound to proteinase inhibitors (free **PSA:PSA**-proteinase inhibitor **complex**) is useful in the diagnosis of patients with prostate cancer.

=> d his

(FILE 'USPAT' ENTERED AT 08:01:18 ON 02 AUG 1999)

L1 32 S (CONJUGATE# OR COMPLEX) (P) (POLYPEPTIDE# OR OLIGOPEPTIDE#  
OR

=> s l1 and (cytotox? or doxorubicin or vinblastine# or vinca(3a)alkaloid?)

10821 CYTOTOX?  
 1757 DOXORUBICIN  
 1313 VINBLASTINE#  
 653 VINCA  
 4419 ALKALOID?  
 563 VINCA(3A)ALKALOID?  
 L2 6 L1 AND (CYTOTOX? OR DOXORUBICIN OR VINBLASTINE# OR VINCA(3A  
 )AL  
 KALOID?)

=> d 12 1-6

1. 5,866,679, Feb. 2, 1999, Peptides; Deborah DeFeo-Jones, et al., 530/322, 324, 326, 328, 329 [IMAGE AVAILABLE]
2. 5,807,978, Sep. 15, 1998, Immunogenic peptides of prostate specific antigen; William J. Kokolus, et al., 530/300; 424/184.1, 185.1, 277.1; 530/326, 327, 403 [IMAGE AVAILABLE]
3. 5,773,292, Jun. 30, 1998, Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood; Neil H. Bander, 435/332; 424/138.1, 141.1, 152.1, 155.1; 435/7.21, 7.23; 530/387.5, 387.7, 388.2, 388.8, 389.1, 389.7, 391.1, 391.3, 391.7 [IMAGE AVAILABLE]
4. 5,736,142, Apr. 7, 1998, Alteration of immune response using pan DR-binding peptides; Alessandro Sette, et al., 424/185.1, 184.1, 193.1; 514/2, 15; 530/300, 327, 332, 868 [IMAGE AVAILABLE]
5. 5,639,656, Jun. 17, 1997, Antibodies reactive with biological markers of benign prostate hyperplasia; George L. Wright, Jr., 435/344.1, 332; 530/388.2, 388.85, 389.1, 391.1, 391.3, 391.7 [IMAGE AVAILABLE]
6. 5,599,686, Feb. 4, 1997, Peptides; Deborah DeFeo-Jones, et al., 435/23; 424/185.1; 435/4, 7.1, 7.23, 18, 24; 530/300, 322 [IMAGE AVAILABLE]